-
Mashup Score: 4Mirabegron is safe but fails to prevent remodelling in patients with mild heart failure - 2 year(s) ago
Your access to the latest cardiovascular news, science, tools and resources.
Source: www.escardio.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Overcoming Obesity 2022 Conference - 2 year(s) ago
Join Obesity Medicine Association Oct. 12-16 in Anaheim, or Nov. 2-5 through the virtual DX. Registration coming soon! Fill out the form to be notified.
Source: Obesity Medicine | FallCategories: Endocrinology, Latest HeadlinesTweet-
Registration Now Open! Overcoming Obesity 2022 Conference, join us in Anaheim, October 12-16 Learn how to treat #obesity utilizing the four pillars at the OMA fall conference @OMAsocial #Nutrition #behavioralmodification #PhysicalActivity #Pharmacotherapy https://t.co/aXBeVtagaR https://t.co/avlgIVXXY2
-
-
Mashup Score: 0Overcoming Obesity 2022 Conference - 2 year(s) ago
Join Obesity Medicine Association Oct. 12-16 in Anaheim, or Nov. 2-5 through the virtual DX. Registration coming soon! Fill out the form to be notified.
Source: Obesity Medicine | FallCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Registration Now Open! Overcoming Obesity 2022 Conference, join us in Anaheim, October 12-16 Learn how to treat #obesity utilizing the four pillars at the OMA fall conference @OMAsocial #Nutrition #behavioralmodification #PhysicalActivity #Pharmacotherapy https://t.co/SHhcrDyJ6n https://t.co/OQA9ViNKFm
-
-
Mashup Score: 2Overcoming Obesity 2022 Conference - 2 year(s) ago
Join Obesity Medicine Association Oct. 12-16 in Anaheim, or Nov. 2-5 through the virtual DX. Registration coming soon! Fill out the form to be notified.
Source: Obesity Medicine | FallCategories: Latest Headlines, PediatricsTweet-
Registration Now Open! Overcoming Obesity 2022 Conference, join us in Anaheim, October 12-16 Learn how to treat #obesity utilizing the four pillars at the OMA fall conference @OMAsocial #Nutrition #behavioralmodification #PhysicalActivity #Pharmacotherapy https://t.co/Wme6zUqbMK https://t.co/mQS0ggZ7hh
-
-
Mashup Score: 0Overcoming Obesity 2022 Conference - 2 year(s) ago
Join Obesity Medicine Association Oct. 12-16 in Anaheim, or Nov. 2-5 through the virtual DX. Registration coming soon! Fill out the form to be notified.
Source: Obesity Medicine | FallCategories: Latest Headlines, PediatricsTweet-
Registration Now Open! Overcoming Obesity 2022 Conference, join us in Anaheim, October 12-16 Learn how to treat #obesity utilizing the four pillars at the OMA fall conference @OMAsocial #Nutrition #behavioralmodification #PhysicalActivity #Pharmacotherapy https://t.co/dEtidVmF5w https://t.co/2Rz41JgcO3
-
-
Mashup Score: 12COVID-19 inpatients do not gain from aspirin and rivaroxaban combined or colchicine alone - 2 year(s) ago
Your access to the latest cardiovascular news, science, tools and resources.
Source: www.escardio.orgCategories: Cardiologists, Latest HeadlinesTweet-
RT @ESCardioNews: #COVID19 inpatients do not gain from #aspirin and rivaroxaban combined or #colchicine alone https://t.co/BPJKnDVv6J #ESC…
-
#COVID19 inpatients do not gain from #aspirin and rivaroxaban combined or #colchicine alone https://t.co/BPJKnDVv6J #ESCCongress #Covid #PharmacoTherapy #cardionews https://t.co/m0DT3c0D6n
-
-
Mashup Score: 5Patients with coronary artery disease should receive P2Y12 inhibitor instead of aspirin - 2 year(s) ago
Your access to the latest cardiovascular news, science, tools and resources.
Source: www.escardio.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Patients with #CoronaryArteryDisease should receive P2Y12 inhibitor instead of #aspirin https://t.co/ak9ykjW0x6 #ESCCongress #PharmacoTherapy https://t.co/7nVDLjzSTF
-
-
Mashup Score: 1Post hoc analysis provides new insights on sacubitril/valsartan in myocardial infarction - 2 year(s) ago
Your access to the latest cardiovascular news, science, tools and resources.
Source: www.escardio.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Post hoc analysis provides new insights on sacubitril/valsartan in #MyocardialInfarction https://t.co/PmN1HL2j5z #ESCCongress #PharmacoTherapy #Infarction #cardionews https://t.co/QHir6YCGCZ
-
-
Mashup Score: 4
Your access to the latest cardiovascular news, science, tools and resources.
Source: www.escardio.orgCategories: Cardiologists, Latest HeadlinesTweet-
RT @ESCardioNews: Long-term evolocumab therapy leads to further reductions in cardiovascular events https://t.co/HJUCIZac1G #ESCCongress #…
-
Long-term evolocumab therapy leads to further reductions in cardiovascular events https://t.co/HJUCIZac1G #ESCCongress #PharmacoTherapy #HeartHealth #cardionews https://t.co/NvsvJ9AUUU
-
-
Mashup Score: 0Study shows longer-term benefit of one-month dual antiplatelet therapy after intervention - 2 year(s) ago
Your access to the latest cardiovascular news, science, tools and resources.
Source: www.escardio.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Study shows longer-term benefit of one-month dual #AntiplateletTherapy after intervention https://t.co/kYEvEUfQqT #ESCCongress #CardiacIntervention #HeartHealth #PharmacoTherapy #cardionews https://t.co/P2hWDPkZGc
-
Research conducted by a consortium of European partners including @escardio concluded that #mirabegron is safe but fails to prevent remodelling in patients with mild #HeartFailure https://t.co/r4N3SXEY9A #AHA22 #cardionews #pharmacology #pharmacotherapy https://t.co/DIDLPMpeyO